News & Updates
Filter by Specialty:
NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC
In a post hoc analysis of two prospective studies, netupitant/palonosetron (NEPA) combined with dexamethasone has demonstrated similar efficacy vs a quadruplet regimen of olanzapine, aprepitant, ondansetron, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in Chinese women with early breast cancer (BC) receiving doxorubicin/cyclophosphamide (AC) in Hong Kong.
NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC
15 Mar 2023
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023
Garlic vegetable intake prevents gastric cancer
Greater dietary intake of allium vegetables, particularly garlic, provides a protective benefit against the development of gastric cancer (GC), suggests a study. This association is independent from vitamin or garlic supplementation.
Garlic vegetable intake prevents gastric cancer
13 Mar 2023
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
13 Mar 2023
Weight status influences urinary function recovery after radical prostatectomy
Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.
Weight status influences urinary function recovery after radical prostatectomy
10 Mar 2023
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
10 Mar 2023
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.
